Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPSR NASDAQ:MLTX NASDAQ:MTSR NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPSRCapstar Special Purpose Acquisition$24.35+0.0%$8.28$6.06▼$12.23$840.21M0.07556,189 shsN/AMLTXMoonLake Immunotherapeutics$49.19+0.6%$43.12$31.42▼$58.26$3.15B1.27386,448 shs199,766 shsMTSRMetsera$37.44+2.8%$28.27$12.30▼$37.99$3.93BN/A899,943 shs130,013 shsPTGXProtagonist Therapeutics$53.41+1.1%$49.88$32.50▼$60.60$3.32B2.26841,057 shs124,018 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPSRCapstar Special Purpose Acquisition+0.14%+0.17%+1.06%+3.88%+272.89%MLTXMoonLake Immunotherapeutics+1.24%+5.42%+6.10%+40.06%+8.69%MTSRMetsera+3.09%+23.63%+3.73%+160.07%+3,640,999,900.00%PTGXProtagonist Therapeutics+1.03%+3.18%-6.28%+23.96%+51.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMLTXMoonLake Immunotherapeutics1.834 of 5 stars3.51.00.00.01.42.50.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics2.5218 of 5 stars3.51.00.00.03.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPSRCapstar Special Purpose Acquisition 0.00N/AN/AN/AMLTXMoonLake Immunotherapeutics 3.00Buy$74.5051.45% UpsideMTSRMetsera 3.00Buy$55.0046.90% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1023.75% UpsideCurrent Analyst Ratings BreakdownLatest CPSR, PTGX, MLTX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/A($1.18) per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/AMTSRMetseraN/AN/AN/AN/A($2.46) per shareN/APTGXProtagonist Therapeutics$434.43M7.62$4.61 per share11.58$11.33 per share4.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPSRCapstar Special Purpose Acquisition-$15.30MN/A0.00∞N/AN/AN/AN/AN/AMLTXMoonLake Immunotherapeutics-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APTGXProtagonist Therapeutics$275.19M$0.7571.37N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)Latest CPSR, PTGX, MLTX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.73N/AN/AN/AN/AN/A8/5/2025Q2 2025PTGXProtagonist Therapeutics-$0.53N/AN/AN/A$8.32 millionN/A5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPSRCapstar Special Purpose AcquisitionN/A0.130.13MLTXMoonLake Immunotherapeutics0.1821.1121.11MTSRMetseraN/A6.556.55PTGXProtagonist TherapeuticsN/A17.2517.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPSRCapstar Special Purpose Acquisition64.87%MLTXMoonLake Immunotherapeutics93.85%MTSRMetseraN/APTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipCPSRCapstar Special Purpose AcquisitionN/AMLTXMoonLake Immunotherapeutics12.02%MTSRMetseraN/APTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPSRCapstar Special Purpose Acquisition234.50 millionN/ANot OptionableMLTXMoonLake Immunotherapeutics264.01 million56.32 millionOptionableMTSRMetsera81105.06 millionN/AN/APTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableCPSR, PTGX, MLTX, and MTSR HeadlinesRecent News About These CompaniesChina Universal Asset Management Co. Ltd. Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 9 at 6:23 AM | marketbeat.comNew York State Teachers Retirement System Has $2.27 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 9 at 3:46 AM | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by AnalystsJuly 9 at 3:37 AM | marketbeat.comTrek Financial LLC Invests $2.83 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 8 at 10:16 AM | marketbeat.comMoody Aldrich Partners LLC Boosts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 4, 2025 | marketbeat.comIllinois Municipal Retirement Fund Reduces Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 2, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.2% - What's Next?July 1, 2025 | marketbeat.comProtagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical StartJuly 1, 2025 | biospace.comBProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for ObesityJune 30, 2025 | usatoday.comCan Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?June 30, 2025 | msn.comPTGX Protagonist Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comProtagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development CandidateJune 26, 2025 | accessnewswire.comAProtagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia VeraJune 24, 2025 | msn.comProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20, 2025 | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20, 2025 | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLCJune 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by CitigroupJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 17, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.comGAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 13, 2025 | marketbeat.comArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPSR, PTGX, MLTX, and MTSR Company DescriptionsCapstar Special Purpose Acquisition NYSE:CPSRCapstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.MoonLake Immunotherapeutics NASDAQ:MLTX$49.19 +0.31 (+0.63%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Metsera NASDAQ:MTSR$37.44 +1.03 (+2.83%) As of 11:33 AM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Protagonist Therapeutics NASDAQ:PTGX$53.41 +0.58 (+1.10%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
